37 results about "Immunocompromised patient" patented technology

This invention describes methods of using anti-B cell antibodies, preferably anti-CD20 antibodies, and most preferably Rituximab, to treat B cell lymphomas of the brain, especially primary central nervous system lymphomas (PCNSLs), and to prevent meningeal relapse. The antibodies can be administered intrathecally alone, or in combination with other chemotherapeutics, such as methotrexate, or other anti-B cell antibodies to treat PCNSL in both immunocompromised and non-immunocompromised patients. These antibodies can also be used to diagnose patients with CNS lymphoma, especially in immunocompromised patients.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

The invention provides methods of treating and preventing asthma, laryngitis, symptomatic gastroesophageal reflux disease, pregnancy-induced gastroesophageal reflux disease, noncardiac chest pains, coughing, apnea, dyspepsia, inflammatory bowel disease, irritable bowel syndrome, gastritis, stress ulcers, bleeding peptic ulcers, acute gastrointestinal bleeding, infectious enteritis, collagenous colitis, lymphocytic colitis, chronic diarrhea in immunocompromised patients, esophageal ulcers in immunocompromised patients, idiopathic gastric acid hypersecretion, gastroparesis, gastrointestinal motility disorders, Zollinger-Ellison syndrome, short bowel syndrome, emesis, regurgitation, early satiety, chronic sore throat, abdominal pain, abdominal bloating, nausea, sour stomach, diarrhea, constipation, bacterial infections, refractory ulcers, gastrointestinal disorders induced by NSAIDs, Barrett's esophagus, gastrointestinal disorders caused by steroids, gastrointestinal disorders induced by cholinergic compounds, and fungal or viral-induced ulcers in the gastrointestinal tract by administering a therapeutically effective amount of at least one proton pump to a patient in need thereof. The invention also provides on demand relief of symptoms associated with gastroesophageal reflux disease (GERD), and provides relief from symptoms caused by the consumption of excessive amounts of food and / or alcohol by administering a therapeutically effective amount of at least one proton pump inhibitor to a patient in need thereof. The invention also provides methods for treating parasitic infections, such as malaria, by administering a therapeutically effective amount of at least one proton pump inhibitor to a patient in need thereof.

A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.

Sanitizing Container and Display is an assembly for maintaining and displaying potted plants, cut flowers and flower arrangements in hospitals, home or other environments where immunocompromised patients or those who suffer allergic disease live. This closed plant-holding container is provided with a air filtered ventilation system that establishes adequate air circulation to the plants while filters the chamber out-flow air and clear out any potential harmful microbe, dust, allergen or fumes from chamber out-flow air that would be dangerous for those patients who lacks normal immune protection or are allergic to plant and flower allergens. This enclosed chamber also is provided with an artificial light source for illumination of the plants or flowers. The object of this invention was to create a completely sealed chamber that makes it possible for immunsuppressed patients or those with sever allergic disease to enjoy the loveliness of these natural beauties in their living environment.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

This application relates to the production and characterization of a mutant strain of Aspergillus fumigatus. The application also relates to a method for inhibiting siderophore biosynthesis in Aspergillus fumigatus and an assay for identifying drug candidates or other agents having potential inhibitory activity. The method may comprise, for example, the step of inhibiting an enzyme catalyzing siderophore biosynthesis, such as L-ornithine N5-oxygenase. In one embodiment the siderophore is a hydroxamate siderophore, such as N′N″N′″-triacetylfusarinine C (TAF) or ferricrocin. A method of preventing or treating fungal infections in a patient is also described comprising administering to the patient an agent suitable for inhibiting fungal secretion of siderophores. The method is particularly useful for immunocompromised patients susceptible to fungal infections caused by Aspergillus fumigatus, such as pulmonary aspergillosis. The invention also relates to diagnostic methods for detecting a biomarker indicative of likely A fumigatus infection in vivo, such as serum presence of TAF.

The invention provides application of arctigenin in preparation of anti-infectious immunity drugs, which belongs to the field of medicine. Arctigenin is a natural monomer extracted from the traditional Chinese medicine burdock; it is discovered that arctigenin can substantially improve the clearance index and the phagocytic index of an immunocompromised patient and enhance non-specific immunity of the patient, exerts good treatment effects on infection caused by parasites, bacteria and viruses and especially has an excellent treatment effect on infectious diseases caused by Gram-positive bacteria. Arctigenin has the advantages of definite therapeutic effects, small toxic and side effects and wide medical application prospects when used for treatment of infectious diseases.

A method for local treatment of severe oral lesions caused by oropharyngeal candidiasis in immunocompromised patients, in particularly having head and neck cancer and undergoing or have undergone radiation therapy, by administering a prolonged release mucoadhesive tablet containing at least one active principle of miconazole. Methods of treating xerostomia in cancer patients having severe oral lesions is also provided.

The present invention provides an attenuated virus derived from a modified vaccinia Ankara virus characterized by loss of the ability to replicate repeatedly in human cell lines. The present invention further describes recombinant viruses derived from the virus and the use of the virus or recombinants thereof as drugs or vaccines. Furthermore, the present invention provides a method of inducing an immune response even in immunocompromised patients, patients who are already immune to vaccine viruses, or patients who are receiving antiviral therapy.

The invention belongs to the field of tuberculosis vaccines, and particularly relates to an antituberculosis vaccine as well as a preparation method and application thereof. Aiming at the problems that an existing vaccine has a poor effect on adults or is unsuitable for hypoimmunity patients and the like, the invention provides the preparation method of the antituberculosis vaccine. The preparation method comprises the following steps: firstly, obtaining a mycobacterium monocell thallus; secondly, interruptedly and circularly irradiating the monocell thallus by adopting rays at low dose to obtain a mycobacterium vaccine, wherein the rays are X-rays, gamma rays or rays generated by an isotope radioactive source Co60; the radiation dose rate lies in that radiation is performed at the rate of10 to 20Gy / min for 8 to 10 times at an interval of 5 to 10 minutes each radiation of 20 minutes. According to the antituberculosis vaccine disclosed by the invention, all antigen characteristics of the thallus are completely retained, stronger specific immune response can be excited more quickly, and effective durable immunity is obtained. The prepared vaccine has the advantages of low toxicity,quick onset and higher safety, and can be used for preventing and treating tituberculosis of immunocompromised patients.

A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.

In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.

A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.

In various aspects, the invention relates to immune tolerant glycosidase therapy. The invention provides methods for treating or preventing infectious disease, including chronic viral infections, and highly contagious infectious agents that present an ongoing challenge for the immune system. The compositions and treatment regimens find use with other antiviral or antimicrobial therapies, as well as in conjunction with vaccination to boost effectiveness and / or extend the duration of protective effect. In certain embodiments, the regimen described herein reduces or eliminates the need for administration of other traditional antiviral or antimicrobial therapies. In various embodiments, the invention finds use in immunocompromised patients to boost immune function.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

The present invention provides an attenuated virus derived from a modified vaccinia Ankara virus characterized by loss of the ability to replicate repeatedly in human cell lines. The present invention further describes recombinant viruses derived from the virus and the use of the virus or recombinants thereof as drugs or vaccines. Furthermore, the present invention provides a method of inducing an immune response even in immunocompromised patients, patients who are already immune to vaccine viruses, or patients who are receiving antiviral therapy.

In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.

The invention provides wheat polypeptide nutrition and healthcare fine dried noodles capable of improving immunity to overcome the technical defect that the improvement effect of nutrition type fine dried noodles in the prior art on the immunity of immunocompromised people is poor. The wheat polypeptide nutrition and healthcare fine dried noodles are prepared from, by weight, 70-85 parts of wheat meal, 0.3-0.8 part of kelp meal, 2-5 parts of aloe juice, 5-8 parts of wheat bioactive peptide, 5-10 parts of coix seed powder, 15-25 parts of ginkgo seeds, 0.1-0.3 part of sucrose fatty acid ester, 8-12 parts of oyster extract and 3-5 parts of wolfberry fruits. The wheat polypeptide nutrition and healthcare fine dried noodles contain various nutritional ingredients, selected nutritional materials are all medicinal and edible materials, and the wheat polypeptide nutrition and healthcare fine dried noodles can significantly improve the immunity of immunocompromised patients and have high promotional value.

The invention discloses the application of phenylpyruvate in the preparation of immune enhancer. The present invention provides phenylpyruvate or a pharmaceutically acceptable salt thereof, or a prodrug of phenylpyruvate in the preparation of an immune enhancer, or in the preparation of a product that enhances macrophage phagocytosis and / or promotes lymphocyte proliferation, or in the preparation of Novel applications in the preparation of products that promote wound healing. The present invention finds that adding phenylpyruvate to the common diet of mice can significantly improve the immunity level of mice and promote wound healing, and the addition of phenylpyruvate is less, so it can be directly added to animal drinking water, feed, and medicines. It has the advantages of being safe, effective, and will not cause toxic and side effects, and can be used for patients with low immune function; it can be used as an immune adjuvant in therapeutic vaccines; it can be used as an immune enhancer in wound healing, immunodeficiency and other treatments. The acid provides a basis as an immune adjuvant and has a good prospect for popularization and application.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.

The invention provides application of a compound cercosporamide in preparation of an immunoenhancer. The compound has immunoenhancement activity and is used for immunocompromised patients suffering cancers, AIDS, immunodeficiency disorder or aging. The cercosporamide has another name of 4-Dibenzofurancarboxamide. The immunoenhancer comprises an active ingredient cercosporamide and auxiliary materials.